Connect Biopharma posts corporate presentation on rademikibart development in asthma, COPD, atopic dermatitis

Connect Biopharma Holdings Ltd.

CNTB

0.00

Connect Biopharma outlined development plans for rademikibart, an anti-IL-4Rα monoclonal antibody with global rights outside greater China.
Phase 2 studies in acute COPD and asthma exacerbations started in 2Q2025, with topline data expected in mid-2026; study is being run by Simcere at no cost to Connect.
Simcere filed an NDA in China for atopic dermatitis in July 2025.
U.S. FDA agreed rademikibart is ready to move into Phase 3 for chronic treatment of asthma and atopic dermatitis, based on results from completed studies.
Presentation highlighted clinical and preclinical comparisons versus dupilumab, including a reported reduction in eosinophils in asthma patients and potential for less frequent dosing in atopic dermatitis.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Connect Biopharma Holdings Ltd. published the original content used to generate this news brief on May 13, 2026, and is solely responsible for the information contained therein.

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.